Euan Thomson - Carl Zeiss Pres Unit
CZMWF Stock | USD 61.22 0.00 0.00% |
Insider
Euan Thomson is Pres Unit of Carl Zeiss Meditec
Age | 60 |
Phone | 49 3641 220 115 |
Web | https://www.zeiss.de/meditec-ag/home.html |
Euan Thomson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Euan Thomson against Carl Zeiss pink sheet is an integral part of due diligence when investing in Carl Zeiss. Euan Thomson insider activity provides valuable insight into whether Carl Zeiss is net buyers or sellers over its current business cycle. Note, Carl Zeiss insiders must abide by specific rules, including filing SEC forms every time they buy or sell Carl Zeiss'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Euan Thomson over a year ago Acquisition by Euan Thomson of 10000 shares of Stereotaxis subject to Rule 16b-3 |
Carl Zeiss Management Efficiency
The company has return on total asset (ROA) of 0.0955 % which means that it generated a profit of $0.0955 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1596 %, meaning that it generated $0.1596 on every $100 dollars invested by stockholders. Carl Zeiss' management efficiency ratios could be used to measure how well Carl Zeiss manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Marco Catalani | EssilorLuxottica Socit anonyme | N/A | |
Steven MD | Carl Zeiss Meditec | N/A | |
Mike Wang | Carl Zeiss Meditec | N/A | |
Holger Haderer | Straumann Holding AG | 54 | |
Augustine JD | HOYA Corporation | 55 | |
Aurelio Sahagun | Straumann Holding AG | 50 | |
Camila Finzi | Straumann Holding AG | 51 | |
Tomoko Nakagawa | HOYA Corporation | N/A | |
Taishi Arashida | HOYA Corporation | N/A | |
Andrew Chang | Carl Zeiss Meditec | N/A | |
Markus Weber | Carl Zeiss Meditec | N/A | |
Rahma Samow | Straumann Holding AG | 44 | |
Alastair Robertson | Straumann Holding AG | 63 | |
Dennis Kaysen | Coloplast AS | N/A | |
KokKien Loh | Straumann Holding AG | 56 | |
Ariel Bauer | EssilorLuxottica Socit anonyme | N/A | |
Ellen Bjurgert | Coloplast AS | N/A | |
Giorgio Iannella | EssilorLuxottica Socit anonyme | N/A | |
Martin Wiechmann | Carl Zeiss Meditec | N/A | |
Laurie Ferguson | Carl Zeiss Meditec | N/A | |
Dorthe Ronnau | Coloplast AS | 57 |
Management Performance
Return On Equity | 0.16 | |||
Return On Asset | 0.0955 |
Carl Zeiss Meditec Leadership Team
Elected by the shareholders, the Carl Zeiss' board of directors comprises two types of representatives: Carl Zeiss inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Carl. The board's role is to monitor Carl Zeiss' management team and ensure that shareholders' interests are well served. Carl Zeiss' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Carl Zeiss' outside directors are responsible for providing unbiased perspectives on the board's policies.
Sebastian Frericks, Director Investor Relations | ||
Laurie Ferguson, Head Devices | ||
Markus Weber, CEO Pres | ||
Martin Wiechmann, Head Unit | ||
Andrew Chang, I Meditec | ||
Euan Thomson, Pres Unit | ||
Steven MD, Chief Devices | ||
Justus Wehmer, CFO, Member of the Management Board | ||
Mike Wang, Head Shanghai |
Carl Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Carl Zeiss a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.16 | |||
Return On Asset | 0.0955 | |||
Profit Margin | 0.15 % | |||
Operating Margin | 0.21 % | |||
Current Valuation | 12.07 B | |||
Shares Outstanding | 89.44 M | |||
Shares Owned By Insiders | 59.10 % | |||
Shares Owned By Institutions | 22.23 % | |||
Price To Earning | 75.63 X | |||
Price To Book | 6.17 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Carl Pink Sheet
Carl Zeiss financial ratios help investors to determine whether Carl Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Carl with respect to the benefits of owning Carl Zeiss security.